Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425256 · ClinicalTrials.gov registry record · Phase 2
Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)
A Phase 2 study, sponsored by Palatin Technologies.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00425256: Completed Phase 2 study, sponsored by Palatin Technologies.
NCT00425256 is a Phase 2 study that has completed, run by Palatin Technologies. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00425256, a Phase 2 study, has completed, sponsored by Palatin Technologies.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
Interventions
- DRUG Bremelanotide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2006-02 |
| Est. Completion | 2007-05 |
| Phase | Phase 2 |
What the finished NCT00425256 record still lists
NCT00425256 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Bremelanotide is the first listed.
NCT00425256 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00425256 about?
NCT00425256 is a clinical study titled "Evaluate the Safety and Efficacy of Bremelanotide in Women With Female Sexual Arousal Disorder (FSAD)". This 8 week at home study is designed to explore efficacy endpoints and evaluate the safety of intranasal Bremelanotide in women with Female Sexual Arousal Disorder. Efficacy will be assessed vs. a parallel placebo group.
What is the current status of trial NCT00425256?
This trial is currently completed. It is a Phase 2 study. The study started on 2006-02. Estimated completion is 2007-05.
What interventions are being tested in trial NCT00425256?
The interventions under investigation include: Bremelanotide (DRUG).
Who is sponsoring clinical trial NCT00425256?
This trial is sponsored by Palatin Technologies, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia